Larry Thompson rejoins PepsiCo
PURCHASE, N.Y. — Larry Thompson has returned to PepsiCo to serve as the company’s EVP government affairs, general counsel and corporate secretary, effective July 30.
Thompson — who previously served as PepsiCo’s SVP government affairs, general counsel and corporate secretary from 2004 to 2011 — will be responsible for PepsiCo’s worldwide legal function and government affairs and public policy organizations. He also will oversee the company’s global compliance function and the company’s philanthropic arm, the PepsiCo Foundation.
Thompson succeeds Maura Abeln Smith, who chose to leave the company to pursue other opportunities.
"We are excited to welcome Larry back to PepsiCo," PepsiCo chairman and CEO Indra Nooyi said. "Larry is a proven and seasoned leader with a strong track record of success at PepsiCo. He has been a highly regarded and trusted advisor, and he has a deep knowledge of, and passion for our business. We will benefit greatly from Larry’s leadership moving forward."
SXC Health Solutions earns specialty Rx accreditation from URAC
LISLE, Ill. — SXC Health Solutions has been awarded specialty pharmacy accreditation from URAC.
URAC said that SXC "demonstrated a commitment to quality health care" by applying for and receiving specialty pharmacy accreditation.
"SXC’s robust specialty sector is a powerful contender in the PBM industry," SXC chairman and CEO Mark Thierer said. "Our URAC accreditation is recognition of the quality and broad scope of our specialty pharmacy commitments. We look forward to continuing to provide unbeatable service and committed support to our clients."
Appeals court rules in favor of Watson in Sanctura XR patent suit
PARSIPPANY, N.J. — The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker’s abbreviated new drug application for an overactive bladder treatment.
The appeals court affirmed a U.S. District Court for the District of Delaware’s decision — made March 31 — that asserted that patents related to Allergan’s Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson’s ANDA for a generic version of Sanctura XR is pending with the Food and Drug Administration.
Sanctura XR had total U.S. sales of approximately $66 million for the 12 months ended in April, according to IMS Health data.